Chronic Cough Market Key Factors and Emerging Opportunities with Current Trends Analysis 2027

Publisher: The Insight Partners

Chronic cough isdefined as a persistent cough that lasts long up to 6-8 weeks. It significantly affects the life of the patients by interrupting sleep, creating vomiting sensation, light-headedness, and even rib fractures. It is caused due tomultiple reasons such as infections, asthma, and gastro esophageal reflux disease (GERD). The chronic cough market growth is attributed to factors suchas rising incidences of chronic cough and growing product developments to treat chronic cough are expected to drive the growth of the market. However, product recalls is the major factor hindering the market growth.

Chronic cough is caused due to asthma, acid reflux from the stomach,and postnasal drip. The conditions such as infection, bronchitis, and lungdiseases are also likely to lead to chronic cough. The condition such as asthmais rising across the world; it is commonly seen among children and adults. Itis a major cause of the growing health burden in the US. For instance,according to the Centers for Disease Control and Prevention (CDC) datapublished in 2019, one among every three people has asthma in the US. AcrossAmerica, over 25 million people live with asthma, which accounts for ~8% inadults, and nearly 8.5% in children.

Request for sample at: https://www.theinsightpartners.com/sample/TIPRE00011584/

Novartis AG; Teva Pharmaceutical Industries Ltd; GlaxoSmithKline plc; Bayer AG; Mylan N.V; Amneal Pharmaceuticals, Inc; Cipla Inc; Reckitt Benckiser Group plc; Sun Pharmaceutical Industries Ltd; and Aurobindo Pharma Ltd are some of the prominentplayers operating in the chronic cough market. The market players are focused onorganic strategies to sustain their position in the market. For instance, in October,2019, Aurobindo Pharma received final approval from the United States Food andDrug Administration (USFDA) to manufacture its generic Guaifenes nextended-release tablets in the strengths of 600 mg and 1,200 mg.

Based on drug class, the chroniccough market is segmented into antihistamines, corticosteroids, decongestants,combination drug, antibiotics, acid blockers, and others drug class. Thecombination drug segment held the largest share of the market in 2019 and thesame segment is anticipated to register the highest CAGR in the market duringthe forecast period. The growth of the market through combination drug segmentsis estimated to grow due to enhanced sales of combination drugs over thecounter and the use of combination drugs targets more symptoms in a single use.

In developing regions such as the Asia Pacific and the Middle East andAfrica, the prevalence of chronic diseases is rising due to pollution andinfections. The countries in these regions are highly populated. Although,cough is a non-communicable disease, it is increasing significantly in thecountries. Several governments are putting their efforts to control theincidences of chronic cough in the respective countries. According to theNational Health Policy 2017, India, premature mortality due to non-communicablediseases, including chronic cough, will be reduced by ~ 25% by 2025.

In the Middle East and Africa, respiratory diseases are rising due toclimatic conditions. The countries surrounded by desserts are prone to the riskof respiratory diseases due to the easy spread of allergens. Over 60 to 70% ofpatients in the countries are diagnosed with respiratory diseases. Anothermajor cause of chronic cough among people in the region is smoking. Nearly 30%of the people are addicted to smoking, which further leads to rising incidencesof chronic cough.

Route of Administration Insights

Based on rout of administration, the chronic cough market is segmentedinto oral, injections, inhalation, and other route of administration. The oral segmentheld the largest share of the market in 2019. However, the inhalation segmentis estimated to register the highest CAGR in the market during the forecast period.

Distribution Channel Insights

Based on distribution channel, the chronic cough market is segmentedinto hospital pharmacy, online pharmacy, and retail pharmacy. The hospitalpharmacy segment held the largest share of the market in 2019. However, the onlinepharmacy segment is estimated to register the highest CAGR in the market duringthe forecast period.

Strategic Insights

Inorganic strategies are the more commonly adopted strategies bycompanies in the chronic cough market, which enables them expand their global footprints,and product and service portfolios. The market players have also adoptedorganic strategies such as product launches strategy to enlarge their global customerbase, which also permits them to maintain their brand name globally.

Purchase Copy of This Report at:  https://www.theinsightpartners.com/buy/TIPRE00011584/

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.  

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com